查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1584109

头孢曲松市场，按适应症、配销通路、国家和地区 - 2024-2032 年行业分析、市场规模、市场份额和预测

Ceftriaxone Market, By Indication, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 303 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告要点

2023年头孢曲松市场规模为201,032万美元，2024年至2032年复合年增长率为3.29%。

头孢曲松市场-市场动态

公众意识的提高以及更容易感染细菌性疾病的老年人口的增加推动了市场需求

头孢曲松经由静脉或肌肉注射给药。口服时，其生物利​​用度低于1%。主要用于治疗泌尿道感染、腹腔内感染、心内膜炎、急性细菌性中耳炎、脑膜炎、肺炎等。此外，头孢曲松可作为青霉素过敏患者神经梅毒的第一线治疗药物。在某些手术之前也会进行注射，以防止术后感染。头孢曲鬆的常见副作用包括疼痛、硬度、压痛、皮肤苍白、腹泻、虚弱和运动时呼吸短促。然而，值得注意的是，头孢曲松对感冒和流感等病毒感染无效。该药物必须有医生处方才能使用。由于泌尿道感染（UTI）发病率的增加、公众意识的提高以及更容易感染细菌性疾病的老年人口的增加，预计全球头孢曲松市场在不久的将来将增长。预计未来几年全球主要慢性病的盛行率将大幅上升。泌尿道感染、急性细菌性中耳炎、腹内感染和其他细菌性疾病的发生不断增加，推动了对头孢曲松注射的需求。泌尿道感染通常是由进入膀胱的细菌引起的，在女性中尤其常见，超过一半的人可能一生中至少经历过一次泌尿道感染。这些感染可能会带来痛苦并造成严重的健康风险。头孢曲松用于治疗泌尿道感染的使用的增加预计将有助于头孢曲松市场的扩大。根据国家生物技术资讯中心的数据，大约 80% 的儿童在其一生中至少会经历一次中耳炎，其中 80% 至 90% 的儿童在达到学龄前可能患有渗出性中耳炎。此外，老年人口的不断增加，特别是在已开发国家，可能会增加对头孢曲松注射液的需求，因为细菌感染在 65 岁以上的人群中更为普遍。

头孢曲松市场-关键见解

根据我们的研究分析师分享的分析，预计全球市场在预测期内（2024-2032 年）每年将以 3.29% 左右的复合年增长率成长

根据适应症细分，预计肺炎将在 2023 年呈现最大市场份额

从配销通路细分来看，医院药局是2023年的主导类型

按地区划分，北美是 2023 年的主要收入来源

头孢曲松市场-細項分析：

全球头孢曲松市场根据适应症、配销通路和地区进行细分。

市场依适应症分为七类：泌尿道感染、腹腔内感染、心内膜炎、急性细菌性中耳炎、脑膜炎、肺炎等。在头孢曲松市场中，肺炎是主要的适应症，这是由于社区获得性和医院获得性肺炎盛行率不断上升，特别是在老年人和免疫功能低下患者等弱势群体中。头孢曲鬆对多种病原体具有广谱功效，使其成为一线治疗药物，因其在治疗重症病例方面的有效性而经常在医院环境中使用。虽然泌尿道感染和脑膜炎等其他适应症也值得注意，但肺炎的高发生率和对有效治疗的迫切需求巩固了其作为头孢曲松主要适应症的地位。

根据配销通路，市场分为三类：医院药房、零售药房和网路药房。在配销通路领域，医院药局在头孢曲松市场中占据主导地位。这种优点主要是由于药物主要用于住院治疗需要立即就医的严重感染。医院药局对于确保需要重症监护的患者及时获得头孢曲松至关重要。儘管零售和线上药局对于门诊管理非常重要，但医院环境中对头孢曲鬆的迫切需求推动了其大部分销售透过医院药局进行，凸显了其所解决的感染的关键性质。

头孢曲松市场-地理洞察

该市场涵盖北美、欧洲、拉丁美洲、亚太地区、中东和非洲。这些地区的参与国家在市场内创造细分市场。 2023年，北美占据头孢曲松市场的最大份额，将其定位为预测期内成长利润丰厚的地区。这种主导地位可归因于细菌感染发生率的上升。此外，该地区受益于技术先进产品的高采用率、大量的医疗保健支出、早期获得创新技术以及政府和慈善组织对医疗保健研究的有利资助。预计这些因素将在未来几年推动头孢曲松市场的扩张。美国成为北美地区的领导者，很大程度上是由于主要行业参与者的存在。

头孢曲松市场-竞争格局：

头孢曲松市场的公司实施各种策略来保持竞争力并促进成长。正在进行的研究和开发工作致力于改进配方，例如创建针对抗药性菌株的缓释版本或联合疗法。与医疗保健提供者和机构的策略联盟促进临床试验并扩大药物在各种医疗环境中的应用。行销活动强调该药物的功效、安全性和治疗常见感染的多功能性，针对处方者和医院。此外，公司经常参与教育活动，以提高人们对正确使用抗生素的认识，并推广头孢曲松作为第一线治疗药物，同时解决抗生素抗药性问题。

最新进展：

2021年9月，印度政府对从中国进口的头孢曲松原料实施反倾销税，以保护国内製造商免受低成本进口产品的影响。

目录

第 1 章：头孢曲松市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场片段
    • 依适应症分類的头孢曲松市场片段
    • 按配销通路分類的头孢曲松市场片段
    • 按国家/地区分類的头孢曲松市场片段
    • 按地区分類的头孢曲松市场片段
  • 竞争洞察

第 3 章：头孢曲松主要市场趋势

  • 头孢曲松市场驱动因素
    • 市场驱动因素的影响分析
  • 头孢曲松市场限制
    • 市场限制影响分析
  • 头孢曲鬆的市场机会
  • 头孢曲松市场未来趋势

第 4 章：头孢曲松产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章：头孢曲松市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：头孢曲松市场格局

  • 2023 年头孢曲松市占分析
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：头孢曲松市场 - 按适应症

  • 概述
    • 按指标分類的细分市场占有率分析
    • 泌尿道感染
    • 腹腔内感染
    • 心内膜炎
    • 急性细菌性中耳炎
    • 脑膜炎
    • 肺炎
    • 其他的

第 8 章：头孢曲松市场 - 按配销通路

  • 概述
    • 按配销通路分類的细分市场份额分析
    • 医院药房
    • 零售药局
    • 网路药局

第 9 章：头孢曲松市场 - 按地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美头孢曲松主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模和预测（按指标）
    • 北美市场规模和预测（按配销通路）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲头孢曲松主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模与预测（按指标）
    • 欧洲市场规模和预测（按配销通路）
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区头孢曲松主要製造商
    • 亚太地区市场规模与预测（按国家）
    • 亚太地区市场规模与预测（依指标）
    • 亚太地区市场规模和预测（按配销通路）
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲头孢曲松主要製造商
    • 拉丁美洲市场规模与预测（按国家）
    • 拉丁美洲市场规模与预测（按指标）
    • 拉丁美洲市场规模和预测（按配销通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲头孢曲松主要製造商
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模及预测（依指标）
    • 中东和非洲市场规模及预测（按配销通路）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 10 章：主要供应商分析-头孢曲松产业

  • 竞争仪表板
  • 公司简介
    • Hikma Pharmaceuticals plc
    • Qilu Pharmaceutical Co. Ltd.
    • Novartis AG
    • Baxter International, Inc.
    • Aurobindo Pharma
    • ACS DOBFAR SPA
    • Orchid Pharma
    • Nectar Lifesciences Ltd.
    • Lupin Pharmaceuticals
    • Others

第 11 章：360 度分析师视角

第 12 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV4060

REPORT HIGHLIGHT

Ceftriaxone Market size was valued at USD 2,010.32 Million in 2023, expanding at a CAGR of 3.29% from 2024 to 2032.

Ceftriaxone is a broad-spectrum cephalosporin antibiotic utilized for treating various bacterial infections. It functions by inhibiting the synthesis of bacterial cell walls, effectively killing or stunting the growth of susceptible bacteria. This antibiotic is commonly advised for conditions such as meningitis, pneumonia, and infections of the skin, urinary tract, and abdomen. Ceftriaxone can be administered intravenously or intramuscularly, ensuring a rapid absorption and effectiveness. Its long half-life allows for once-daily dosing in many instances, making it a convenient option for both hospital and outpatient settings. Ceftriaxone is recognized for its efficacy against diverse range of pathogens, establishing it as a cornerstone of an empirical antibiotic therapy. As a cephalosporin beta-lactam antibiotic, it targets bacterial infections caused by typically susceptible gram-positive organisms. In vitro studies have demonstrated that ceftriaxone is effective against gram-positive, gram-negative, and anaerobic bacteria. Its bactericidal action is attributed to its inhibition of cell wall synthesis, which occurs through binding to penicillin-binding proteins (PBPs).

Ceftriaxone Market- Market Dynamics

Increasing awareness among the public, and the rising geriatric population that is more susceptible to bacterial diseases to propel market demand

Ceftriaxone is administered via intravenous or intramuscular injection. When taken orally, its bioavailability is less than 1%. It is primarily used to treat urinary tract infections, intra-abdominal infections, endocarditis, acute bacterial otitis media, meningitis, and pneumonia. Additionally, ceftriaxone serves as the first-line treatment for neurosyphilis in patients who are allergic to penicillin. The injection is also given prior to certain surgeries to prevent post-operative infections. Common side effects of ceftriaxone include pain, hardness, tenderness, pale skin, diarrhea, weakness, and shortness of breath during exercise. However, it is important to note that ceftriaxone is ineffective against viral infections such as colds and the flu. The medication is available only with a doctor's prescription. The global ceftriaxone market is expected to grow in the near future due to the increasing incidence of urinary tract infections (UTIs), heightened awareness among the public, and the rising geriatric population that is more susceptible to bacterial diseases. The prevalence of major chronic diseases worldwide is anticipated to rise significantly in the coming years. The demand for ceftriaxone injections is being driven by the growing occurrence of UTIs, acute bacterial otitis media, intra-abdominal infections, and other bacterial conditions. UTIs, often caused by bacteria entering the bladder, are particularly common among women, with more than half likely to experience at least one UTI in their lifetime. These infections can be painful and pose serious health risks. The increasing use of ceftriaxone for treating UTIs is projected to contribute to the expansion of the ceftriaxone market. According to the National Center for Biotechnology Information, approximately 80% of children are expected to experience at least one episode of otitis media during their lifetime, with 80% to 90% likely to have otitis media with effusion before reaching school age. Moreover, the rising geriatric population, particularly in developed countries, is likely to increase the demand for ceftriaxone injections, as bacterial infections are more prevalent among individuals over the age of 65.

Ceftriaxone Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 3.29% over the forecast period (2024-2032)

Based on Indication segmentation, pneumonia was predicted to show maximum market share in the year 2023

Based on Distribution Channel segmentation, hospital pharmacies was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Ceftriaxone Market- Segmentation Analysis:

The Global Ceftriaxone Market is segmented on the basis of Indication, Distribution Channel, and Region.

The market is divided into seven categories based on Indication: Urinary Tract Infections, Intra-abdominal Infections, Endocarditis, Acute Bacterial Otitis Media, Meningitis, Pneumonia and Others. In the ceftriaxone market, pneumonia is the leading indication, driven by the rising prevalence of both community-acquired and hospital-acquired pneumonia, particularly among vulnerable groups such as the elderly and immunocompromised patients. Ceftriaxone's broad-spectrum efficacy against a wide range of pathogens positions it as a first-line treatment, frequently administered in hospital settings for its effectiveness in managing severe cases. While other indications, such as urinary tract infections and meningitis, are also notable, the high incidence of pneumonia and the urgent need for effective treatment solidify its status as the primary indication for ceftriaxone.

The market is divided into three categories based on Distribution Channel: Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. In the distribution channel segment, hospital pharmacies are the dominant in the ceftriaxone market. This predominance is primarily due to drug's primary use in inpatient settings for treating serious infections that necessitate immediate medical attention. Hospital pharmacies are essential for ensuring timely access to ceftriaxone for patients requiring critical care. Although retail and online pharmacies are significant for outpatient management, the urgent demand for ceftriaxone in hospital environments drives the majority of its sales through hospital pharmacies, highlighting the critical nature of the infections it addresses.

Ceftriaxone Market- Geographical Insights

This market covers North America, Europe, Latin America, Asia Pacific, and the Middle East and Africa. Participating nations within these regions create sub-segments within the market. In 2023, North America held the largest share of the ceftriaxone market, positioning itself as a highly lucrative region for growth during the forecast period. This dominance can be attributed to the rising incidence of bacterial infections. Furthermore, the region benefits from a high adoption rate of technologically advanced products, significant healthcare expenditure, early access to innovative technologies, and favorable funding from governments and charitable organizations for healthcare research. These factors are expected to drive the expansion of the ceftriaxone market in the coming years. The U.S. emerged as the leader within North America, largely due to the presence of key industry players.

Ceftriaxone Market- Competitive Landscape:

Companies in the ceftriaxone market implement a variety of strategies to remain competitive and foster growth. Ongoing research and development efforts are dedicated to improving formulations, such as creating extended-release versions or combination therapies aimed at resistant strains. Strategic alliances with healthcare providers and institutions facilitate clinical trials and broaden the drug's application in various medical environments. Marketing initiatives emphasize the drug's efficacy, safety profile, and versatility in treating common infections, targeting both prescribers and hospitals. Furthermore, companies often participate in educational campaigns to raise awareness about the appropriate use of antibiotics, promoting ceftriaxone as a first-line treatment while addressing concerns regarding antibiotic resistance.

Recent Developments:

In September 2021, the Government of India implemented an anti-dumping duty on ceftriaxone raw materials imported from China to safeguard domestic manufacturers from low-cost imports.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CEFTRIAXONE MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Hikma Pharmaceuticals plc
  • Qilu Pharmaceutical Co. Ltd.
  • Novartis AG
  • Baxter International, Inc.
  • Aurobindo Pharma
  • ACS DOBFAR S.P.A.
  • Orchid Pharma
  • Nectar Lifesciences Ltd.
  • Lupin Pharmaceuticals
  • Others

GLOBAL CEFTRIAXONE MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Urinary Tract Infections
  • Intra-abdominal Infections
  • Endocarditis
  • Acute Bacterial Otitis Media
  • Meningitis
  • Pneumonia
  • Others

GLOBAL CEFTRIAXONE MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL CEFTRIAXONE MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Ceftriaxone Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Ceftriaxone Market Snippet by Indication
    • 2.1.2. Ceftriaxone Market Snippet by Distribution Channel
    • 2.1.3. Ceftriaxone Market Snippet by Country
    • 2.1.4. Ceftriaxone Market Snippet by Region
  • 2.2. Competitive Insights

3. Ceftriaxone Key Market Trends

  • 3.1. Ceftriaxone Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Ceftriaxone Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Ceftriaxone Market Opportunities
  • 3.4. Ceftriaxone Market Future Trends

4. Ceftriaxone Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Ceftriaxone Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Ceftriaxone Market Landscape

  • 6.1. Ceftriaxone Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Ceftriaxone Market - By Indication

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Indication, 2023 & 2032 (%)
    • 7.1.2. Urinary Tract Infections
    • 7.1.3. Intra-abdominal Infections
    • 7.1.4. Endocarditis
    • 7.1.5. Acute Bacterial Otitis Media
    • 7.1.6. Meningitis
    • 7.1.7. Pneumonia
    • 7.1.8. Others

8. Ceftriaxone Market - By Distribution Channel

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
    • 8.1.2. Hospital Pharmacies
    • 8.1.3. Retail Pharmacies
    • 8.1.4. Online Pharmacies

9. Ceftriaxone Market- By Geography

  • 9.1. Introduction
    • 9.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 9.2. North America
    • 9.2.1. Overview
    • 9.2.2. Ceftriaxone Key Manufacturers in North America
    • 9.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.2.4. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.2.5. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.2.6. U.S.
      • 9.2.6.1. Overview
      • 9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.2.6.3. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.2.6.4. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.2.7. Canada
      • 9.2.7.1. Overview
      • 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.2.7.3. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.2.7.4. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.3. Europe
    • 9.3.1. Overview
    • 9.3.2. Ceftriaxone Key Manufacturers in Europe
    • 9.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.3.4. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.3.5. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.3.6. Germany
      • 9.3.6.1. Overview
      • 9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.6.3. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.3.6.4. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.3.7. Italy
      • 9.3.7.1. Overview
      • 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.7.3. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.3.7.4. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.3.8. United Kingdom
      • 9.3.8.1. Overview
      • 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.8.3. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.3.8.4. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.3.9. France
      • 9.3.9.1. Overview
      • 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.9.3. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.3.9.4. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.3.10. Russia
      • 9.3.10.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.10.2. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.3.10.3. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.3.11. Netherlands
      • 9.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.11.2. Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.3.11.3. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.3.12. Sweden
      • 9.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.12.2. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.3.12.3. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.3.13. Poland
      • 9.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.13.2. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.3.13.3. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.3.14. Rest of Europe
      • 9.3.14.1. Overview
      • 9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.14.3. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.3.14.4. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.4. Asia Pacific (APAC)
    • 9.4.1. Overview
    • 9.4.2. Ceftriaxone Key Manufacturers in Asia Pacific
    • 9.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.4.4. Asia Pacific Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.4.5. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.4.6. India
      • 9.4.6.1. Overview
      • 9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.6.3. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.4.6.4. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.4.7. China
      • 9.4.7.1. Overview
      • 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.7.3. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.4.7.4. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.4.8. Japan
      • 9.4.8.1. Overview
      • 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.8.3. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.4.8.4. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.4.9. South Korea
      • 9.4.9.1. Overview
      • 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.9.3. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.4.9.4. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.4.10. Australia
      • 9.4.10.1. Overview
      • 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.10.3. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.4.10.4. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.4.11. Thailand
      • 9.4.11.1. Overview
      • 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.11.3. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.4.11.4. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.4.12. Indonesia
      • 9.4.12.1. Overview
      • 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.12.3. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.4.12.4. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.4.13. Philippines
      • 9.4.13.1. Overview
      • 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.13.3. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.4.13.4. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.4.14. Rest of APAC
      • 9.4.14.1. Overview
      • 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.14.3. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.4.14.4. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.5. Latin America
    • 9.5.1. Overview
    • 9.5.2. Ceftriaxone Key Manufacturers in Latin America
    • 9.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.5.4. Latin America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.5.5. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.5.6. Brazil
      • 9.5.6.1. Overview
      • 9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.6.3. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.5.6.4. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.5.7. Mexico
      • 9.5.7.1. Overview
      • 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.7.3. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.5.7.4. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.5.8. Argentina
      • 9.5.8.1. Overview
      • 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.8.3. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.5.8.4. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.5.9. Colombia
      • 9.5.9.1. Overview
      • 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.9.3. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.5.9.4. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.5.10. Rest of LATAM
      • 9.5.10.1. Overview
      • 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.10.3. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.5.10.4. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.6. Middle East and Africa
    • 9.6.1. Overview
    • 9.6.2. Ceftriaxone Key Manufacturers in Middle East and Africa
    • 9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.6.4. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.6.5. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.6.6. Saudi Arabia
      • 9.6.6.1. Overview
      • 9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.6.3. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.6.6.4. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.6.7. United Arab Emirates
      • 9.6.7.1. Overview
      • 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.7.3. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.6.7.4. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.6.8. Israel
      • 9.6.8.1. Overview
      • 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.8.3. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.6.8.4. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.6.9. Turkey
      • 9.6.9.1. Overview
      • 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.9.3. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.6.9.4. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.6.10. Algeria
      • 9.6.10.1. Overview
      • 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.10.3. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.6.10.4. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.6.11. Egypt
      • 9.6.11.1. Overview
      • 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.11.3. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.6.11.4. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.6.12. Rest of MEA
      • 9.6.12.1. Overview
      • 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.12.3. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 9.6.12.4. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

10. Key Vendor Analysis- Ceftriaxone Industry

  • 10.1. Competitive Dashboard
  • 10.2. Company Profiles
    • 10.2.1. Hikma Pharmaceuticals plc
    • 10.2.2. Qilu Pharmaceutical Co. Ltd.
    • 10.2.3. Novartis AG
    • 10.2.4. Baxter International, Inc.
    • 10.2.5. Aurobindo Pharma
    • 10.2.6. ACS DOBFAR S.P.A.
    • 10.2.7. Orchid Pharma
    • 10.2.8. Nectar Lifesciences Ltd.
    • 10.2.9. Lupin Pharmaceuticals
    • 10.2.10. Others

11. 360 Degree Analyst View

12. Appendix

  • 12.1. Research Methodology
  • 12.2. References
  • 12.3. Abbreviations
  • 12.4. Disclaimer
  • 12.5. Contact Us